Deutsche Bank Analyst Says Fresenius Shares Poised to Outperform

Deutsche Bank analyst Falko Friedrichs says Fresenius is well-positioned to outperform, citing continued beats on expectations and steps to expand its biosimilars business. The German healthcare group beat forecasts and nudged up guidance, according to the report.